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INTRODUCTION
Diabetes mellitus (DM) represents one of the most important 
health problems worldwide and, according to recent estimations, 
it is likely to worsen to critical levels in the next decades, with the 
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ABSTRACT
With the increasing patients and limited therapeutic options, diabetic nephropathy (DN) is a long‑term complication of diabetic mellitus. 
The precise mechanism of DN is not yet fully understood and the effective blockade of the progression of nephropathy remains a 
therapeutic challenge. Application of traditional Chinese medicine (TCM) for diabetes and its related complications has received 
increasing attention due to its wide availability, low side effects, and proven therapeutic mechanisms and benefits. In the current review, 
we mainly focus on the recent laboratory studies of the TCM formulas including Wu‑Ling‑San (Poria Five Powder; 五苓散 Wǔ Líng Sǎn), 
Danggui‑Buxue‑Tang (Tangkuei and Astragalus Decoction; 當歸補血湯 Dāng Guī Bǔ Xuè Tang), and Danggui‑Shaoyao‑San (Tangkuei 
and Paeonia Formula; 當歸芍藥散 Dāng Guī Sháo Yào Sǎn), conducted by the Committee on Chinese Medicine and Pharmacy 
at the Department of Health of Taiwan Government, in the amelioration of DN. These selected TCM formulas have anti‑diabetic 
properties, with antihyperglycemic activity accompanied by amelioration of advanced glycation end product–mediated renal damage in 
streptozotocin‑induced diabetic rats. However, the renoprotective effects of the selected TCM formulas did not correlate with suppressing 
renal renin–angiotensin system hyperactivity in diabetic rats. These TCM formulas also have the capacity to ameliorate the defective 
antioxidative defense system, leading to modulation of the oxidative stress, thereby resulting in downregulation of nuclear factor‑kB as 
well as transforming growth factor‑β1 and, consequently, attenuation of extracellular matrix components such as fibronectin or type IV 
collagen expression in diabetic renal cortex tissue. More detailed mechanistic researches and long‑term clinical evaluations, as well 
as evaluation of safety of the selected TCM formulas are needed for their future applications in DN therapy.
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great concern that this disease is rising rapidly in younger popula‑
tion groups, including children and adolescents.[1] According to data 
from the International Diabetes Federation, the number of diabetics 
older than 20 years will rise from 285 million in 2010 to 439 mil‑
lion in 2030.[2] Therefore, target organ complications secondary to 
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diabetes, especially micro and macrovascular complications, will 
be one of the most important medical concerns in the near future.
Among the diabetic complications, nephropathy is the most 
common cause of end‑stage renal disease (ESRD) in developed 
countries and a major cause of morbidity and mortality in patients 
with diabetes.[3] It is characterized by structural abnormalities 
including hypertrophy of both glomerular and tubular elements, 
increase in the thickness of glomerular basement membranes, and 
progressive accumulation of extracellular matrix components.[4] It 
also results in functional alterations including the early increase in 
the glomerular filtration rate with intraglomerular hypertension, 
subsequent proteinuria, systemic hypertension, and eventual loss 
of renal function.[4] The development of irreversible renal change 
in DM, such as glomerulosclerosis and tubulointerstitial fibrosis, 
results ultimately in ESRD.[3] Measures to prevent the appearance 
and progression of diabetic nephropathy (DN) should therefore be 
instituted as early as possible. Clarification of the pathogenesis of 
DN and development of novel and effective therapeutic strategies 
are therefore high priorities.
Current therapies for DN
DN has several distinct phases of development and multiple 
mechanisms contribute to the development of the disease and its 
outcomes. Although adequate control of blood glucose levels may 
prevent the development of complications, it is difficult to achieve 
strict blood glucose control, leading to a year‑by‑year increase in 
the number of patients with diabetes.[5] Beyond glycemic control, 
other metabolic factors have been shown to be involved in the 
development of diabetic kidney disease, i.e. advanced glycation 
end products (AGEs).[6] Furthermore, an adequate control of high 
blood pressure and treatment of microalbuminuria are the major 
therapeutic targets.[7] To achieve adequate blood pressure control, 
a combination therapy with different classes of antihypertensive 
agents is often necessary, especially including angiotensin‑con‑
verting enzyme inhibitors (ACEIs) and angiotensin receptor 
blockers (ARBs).[8] Besides hyperglycemia and high blood pres‑
sure, other risk factors have been identified in the development 
or progression of diabetic kidney disease, such as hyperlipidemia 
and obesity.[4] Increased lipid peroxidation in the kidney implies 
the level of susceptibility to diabetic oxidative stress, leading 
to diabetic complications. From this viewpoint, prevention of 
hyperlipidemia and/or lipid peroxidation resulting from oxida‑
tive stress is considered to play a crucial role in protection from 
disorders associated with diabetes.[9] The interventions in general 
clinical use are not capable of efficiently slowing or reversing the 
progression of nephropathy. Therefore, interventions that could 
optimally delay the development of DN are required.
RECENT FINDINGS FROM THE SELECTED 
TRADITIONAL CHINESE MEDICINAL 
FORMULAS FOR DN TREATMENT
Up to now, there have been many experiments focusing on the 
treatment of diabetes and its complications with traditional Chinese 
medicine (TCM) because of less toxicity and/or side effects, if the 
herbs or Chinese prescriptions are prescribed strictly according to 
the recommendation of the pharmacopoeia with attention to their 
origin, dose, way of preparation, and duration of intake. Following 
the most general principles of TCM, diabetes affects a patient’s 
“qi (energy/life‑force)” to cause weakness in circulatory system 
function. In TCM, the spleen is a source of vital energy and blood, 
and a controller of blood circulation. When spleen qi is weak, its 
blood controlling function is disturbed; further, the production of 
blood and “qi” is decreased, leading to ischemia and anoxia of 
kidney tissue and kidney capillary endothelial cells are damaged. 
Once the kidney endothelial cells are damaged, it will attract in‑
filtration of inflammatory cells in the blood circulation and release 
the pathogenic inflammatory mediators. So, the process of the 
renal fibrosis is started.[3] Treatment of diabetes by the principles 
of TCM, therefore, emphasizes improvements of “qi” and circu‑
latory function.[10] In prescribing formulas, spleen‑strengthening 
formulas such as Wu‑Ling‑San (WLS; Poria Five Powder; 五苓散 
Wǔ Líng Sǎn) could eliminate fluid in the lower and middle body, 
help dispel moisture, and restore blood circulation.[11,12]
It should be noted that the scientific basis for the therapeutic 
effects of TCM, which utilizes herbs for therapy under the guidance 
of traditional theory, has been established in the literature reports. 
Rehmannia Six Formula (RF; 六味地黃丸 Liù Wèi Dì Huáng Wán) 
is a formula that is commonly used in TCM to treat patients with 
diabetes. There are six herbs that make up RF, namely Rehmannia 
glutinosa, Fructus corni, Dioscorea, Poria cocos, Alisma, and 
Paeonia suffruticosa. On the basis of the publications found in 
PubMed during the period 2000–2009, RF appears to have benefi‑
cial effects on blood glucose, neuropathy, and nephropathy. There 
is also evidence of anti‑inflammatory and antioxidant effects.[13] 
Pharmacological studies have revealed that other TCM formulas 
also exert a positive influence on diabetes. To gather information 
regarding the use of traditional Chinese formulas in the treatment 
of DN, we performed a literature search in PubMed using specific 
search terms such as traditional Chinese formulas and DN. In the 
current review, we mainly focus on the recent laboratory studies of 
the TCM formulas including WLS, Danggui‑Buxue‑Tang (DBT; 
當歸補血湯 Dāng Guī Bǔ Xuè Tang), and Danggui‑Shaoyao‑San 
(DSS; 當歸芍藥散 Dāng Guī Sháo Yào Sǎn), conducted by the 
Committee on Chinese Medicine and Pharmacy at the Department 
of Health of Taiwan Government, in the amelioration of DN. The 
appearance and weight of each herb in formulas according to an‑
cient medical literature are shown in Figure 1.
Wu‑Ling‑San (WLS; Poria Five Powder; 五苓散 Wǔ Líng Sǎn)
WLS, also called Hoelen Five Herb Formula, is a classic 
herbal combination for promoting water metabolism and is 
composed of four water‑draining herbs including hoelen (Sclero‑
tium Poriae Cocos; 茯苓 Fú Líng), alisma (Alismatis Rhizoma; 
澤瀉 Jí Xiè), polyporus sclerotium (Sclerotium polypori Umbrel‑
lati; 豬苓 Zhū Líng), and bighead atractylodes rhizome (Rhizoma 
Atractylodis Macrocephalae; 白朮 Bái Zhú) plus a warm herb, 
cinnamon twig (Ramulus Cinnamomi Cassiae; 桂枝 Guì Zhī). 
WLS has been widely used to treat edema, such as scrotal edema 
and cardiac edema, urine retention or difficult urination, and has 
been applied for promoting blood circulation.[11,12] It has been re‑
ported that WLS suppresses the development of nephrocalcinosis 
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induced by a high phosphorus diet in rats, inhibited the synthe‑
sis and expression of endothelin‑1 in rats with anti‑glomerular 
basement membrane nephritis, and reduced calcium oxalate 
crystallization in human urine.[14‑16] Currently, it has been demon‑
strated that WLS possesses the therapeutic potential to ameliorate 
adriamycin‑induced nephrotic syndrome in rats.[17] It provides an 
important pharmacological and therapeutic basis of WLS in the 
treatment of various kidney diseases.
Danggui‑Buxue‑Tang (DBT; 當歸補血湯 Dāng Guī Bǔ Xuè 
tang)
DBT, also known Tangkuei liù wèi dì huángand Astragalus 
decoction, is widely employed in TCM because of the marked 
hematopoietic properties of this preparation.[18] DBT was formu‑
lated originally during the Jin dynasty with two main ingredients, 
angelica root (Radix Angelicae Sinensis; 當歸根 Dāng Guī Gēn) 
and astragalus root (Radix Astragali; 黃芪 Huáng Qí) in a ratio 
of 1:5.[19] It has been documented that higher amounts of angelica 
root–derived ferulic acid, and astragalus root–derived astragalo‑
side IV, calycosin, and formononetin were found in DBT, with 
angelica root and astragalus root in a 1:5 ratio.[20] With this ratio 
of its ingredients, DBT has been found to reduce menopausal 
symptoms.[21] This formula treats consumptive fatigue and internal 
injury which causes deficient “qi” and blood, and “floating yang” 
appears externally. Recent findings indicate that DBT has the abil‑
ity to promote hematopoietic function, stimulate cardiovascular 
circulation, prevent osteoporosis, and antagonize the activity of 
tumors.[19,22] Actually, DBT has an ability to lower higher plasma 
glucose in streptozotocin‑induced diabetic rats (STZ‑diabetic rats), 
the type 1 diabetes‑like animal model.[23] DBT also displays the 
characteristic of rosiglitazone to ameliorate insulin resistance in‑
duced by a high‑fructose diet in rats.[24] It seems that this traditional 
Chinese herbal preparation is valued in the glucose homeostasis 
and may therefore be utilized as adjuvant therapy for control of 
diabetes and its complications.
Danggui‑Shaoyao‑San (DSS; 當歸芍藥散 Dāng Guī Sháo 
Yào Sǎn)
DSS, also called Tangkuei and Paeonia Formula, comprising 
white peony root (Radix Paeoniae Alba), angelica root, chuanxiong 
rhizome (Rhizoma Chuanxiong), hoelen, bighead atractylodes rhi‑
zome and alisma, is a widely used formula of TCM derived from 
“Jingui Yaolue,” a medical classic written by Zhongjing Zhang in 
the Eastern Han Dynasty. Identification and determination of the 
major constituents in traditional Chinese medicinal prescriptions is 
constantly being carried out. Researchers have much information 
on several active fractions and components from DSS.[25] Monoter‑
pene glycosides, phenolic compounds, and phthalides are the most 
representative components of DSS as far as both the contents and 
their biological activities are concerned. Monoterpene glycosides 
are responsible for the efficacy of white peony root. A case in point 
is albiflorin and paeoniflorin, which exhibits analgesia, spasmolysis, 
anti‑inflammation, and anticoagulation activities.[26] Phenolic acids 
and phthalides in angelica root and chuanxiong rhizome also have 
vasodilatative, antithrombotic, antioxidative, anti‑inflammatory, 
and muscle relaxant effects.[27] In addition, atractylenolides from 
bighead atractylodes rhizome showed gastrointestinal inhibitory, 
anti‑inflammatory, and antioxidative activity.[28] Meanwhile, cyto‑
toxic, anti‑inflammatory, and antioxidant activities of triterpenes in 
alisma and hoelen have also been documented.[29,30] DSS has been 
used in China as a blood‑activating and stasis‑eliminating drug to 
treat gynecological disorders such as dysmenorrhea, amenorrhea, 
and infertility without observation of any side effects for thousands 
of years.[31,32] Recent studies show that it also possesses the capabil‑
ity of treating neural dysfunctions such as senile dementia, memory 
loss, and other cognitive disorders; therefore, the formula is used 
as a remedy for Alzheimer’s disease in Japan.[33,34]
BENEFICIAL EFFECTS OF THE SELECTED 
TCM FORMULAS IN DN
DN is a progressive disease that causes glomerular fibrosis and 
impairment of renal function, with progression over time. Urinary 
albumin excretion has been demonstrated to be a good clinical pre‑
dictor of renal lesions in DN.[35] In our previous study, the increase 
in urinary albumin concentration corresponding to hyperglycemia 
was more pronounced 8 weeks following the induction of diabetes 
by STZ. In addition, serum creatinine and blood urea nitrogen 
levels and creatinine clearance, generally considered as markers 
of renal function, were higher in STZ‑diabetic rats than those 
of non‑diabetic group, implying the presence of diabetic kidney 
disease with renal hyperfiltration.[23,36,37] Repeated treatment with 
DBT (3.6 g/kg/day), WLS (2.5 g/kg/day), or DSS (2.8 g/kg/day) 
for 8‑12 weeks could attenuate albuminuria and ameliorate the loss 
of renal function and glomerular hyperfiltration in STZ‑diabetic 
Figure 1. The appearance and the weight of each herb in (a) Wu‑Ling‑San, (b) Danggui‑Buxue‑Tang, and (c) Danggui‑Shaoyao‑San
cba
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rats.[23,36,37] The selected traditional Chinese medicinal formulas be 
beneficial in the treatment of DN has been considered.
In addition to the increase in urinary albumin excretion, one 
of the most remarkable renal pathological findings in DN is me‑
sangial expansion due to pathological accumulation of extracel‑
lular matrix (ECM) components, such as fibronectin and type IV 
collagen, in glomeruli.[38] In our STZ‑induced type‑1 diabetic rats, 
not only fibronectin but also type IV collagen accumulated in the 
mesangial area of glomeruli; on the contrary, the protein was ex‑
pressed at lower levels in glomeruli of STZ‑diabetic rats treated for 
8‑12 weeks with WLS (2.5 g/kg/day), DBT (3.6 g/kg/day), or DSS 
(2.8 g/kg/day). Furthermore, the increased kidney weight as well 
as accelerated mesangial expansion in glomeruli of STZ‑diabetic 
rats were remissive by treatment with these prescriptions.[23,36,37] 
The results reflected these prescriptions have potential effects on 
the deterioration of renal fibrosis through reduction of renal ECM 
accumulation in STZ‑diabetic rats, which may lead to ameliorate 
or delay the development of advanced diabetic renal injury.
POSSIBLE MECHANISMS OF ACTION 
OF THE SELECTED TCM FORMULAS TO 
AMELIORATE DN
Suppression of TGF‑β expression by the selected TCM 
formulas to ameliorate DN
Members of the transforming growth factor (TGF)‑β family 
of factors are established to modulate cell growth and differen‑
tiation.[39] TGF‑β family members include TGF‑β1, TGF‑β2, and 
TGF‑β
3
, each of which is encoded by a different gene on a dif‑
ferent chromosome. TGF‑β1 is the most predominant (~90%) and 
active TGF‑β family member. TGF‑β is mainly synthesized in 
blood‑forming cells such as platelets, macrophages, and mono‑
nuclear cells. In the kidney, TGF‑β is provided by infiltrating 
white cells (macrophages, T‑cells, and B‑cells) and activated renal 
cells (tubular cells, glomerular cells, and mesangial cells). Renal 
cells are also targets of TGF‑β signaling. After interacting with 
the TGF‑β receptor (TβR), TGF‑β crosses the plasmalemma via 
the Smad protein to regulate nuclear gene transcription.[40]
Previous studies have revealed that kidney glomerular and 
tubular TGF‑β1 mRNA and protein concentrations are elevated 
in STZ‑diabetic animals, as well as in diabetes‑prone BioBreed‑
ing rats, non‑obese diabetic mice, and obese, hyperglycemic, 
insulin‑resistant type‑2 diabetic db/db mice.[41,42] Additionally, 
expression of TβR mRNA and protein in the kidney is increased 
in diabetic animals, and TGF‑β1 synthesis by mononuclear cells 
in peripheral blood is elevated in diabetic patients.[43] TGF‑β1 has 
been shown to induce collagen secretion from kidney cells and to 
inhibit collagenase activity, leading to accumulation of ECM.[44] 
TGF‑β1 also transforms kidney epithelial cells into fibrocytes, 
thereby increasing the rates of ECM deposition and appearance 
of nephrosclerosis.[45] Moreover, TGF‑β1 causes kidney glomerular 
and tubular cells to undergo hypertrophy, resulting in increased 
kidney size.[46] Thus, TGF‑β1 has been considered as a therapeutic 
target in fibrotic disease such as DN and other chronic kidney 
diseases. It was worth noting that the overexpression of TGF‑β1 
in glomeruli of diabetic rats was lessened with WLS, DBT, or DSS 
treatment.[23,36,37] Thus, the nephropathy‑protective effects of the 
selected TCM formulas were mediated by the downregulation of 
TGF‑β1 expression.
The plasma glucose lowering effects of the selected TCM 
formulas are associated with the DN amelioration
Both hyperglycemia and hyperlipidemia have been linked to 
diabetic complications, especially renal damage.[47] In our previous 
study, significant increase in fasting blood glucose in STZ‑diabetic 
was observed when compared to normal control group and this 
change was more marked at the 8th week following diabetes induc‑
tion. Furthermore, the blood glucose lowering effect was obvious 
when STZ‑diabetic rats were treated with DBT at the daily dosage 
of 3.6 g/kg for 8 weeks.[23] The plasma glucose lowering effect 
was marked when STZ‑diabetic rats received WLS treatment at 
2.5 g/kg/day for 10 weeks.[36] DSS also ameliorated the hypergly‑
cemia in STZ‑diabetic rats at the end of the 12‑weeks treatment.[37] 
Neither DBT, nor WLS or DSS at any dosage made changes in 
the plasma levels of cholesterol and triglyceride in STZ‑diabetic 
rats throughout the study period.[23,36,37] The lower blood glucose 
levels induced by treatment of STZ‑diabetic rats with WLS, DBT, 
or DSS represents an obvious factor in the assessment of the 
mechanism (s) by which the selected TCM formulas prevent renal 
functional and structural changes that might be linked to reduce 
the hyperglycemic state in diabetic rats.
Inhibition of AGE–RAGE pathway by the selected TCM 
formulas to ameliorate DN
The hyperglycemia condition, a chronic metabolic disorder 
of glucose, results in irreversible tissue damage by the protein 
glycation reaction, which leads to the formation of glycosylated 
protein and AGEs.[4] It has been reported that AGEs trigger the 
activation of nuclear factor kappa B (NF‑κB) by interaction with 
receptor for AGE (RAGE). NF‑κB is present in the cytoplasm, as a 
complex with its inhibitory protein known as IκB. After activation 
by a number of physiological and nonphysiological stimuli, IκB 
dissociates from NF‑κB within minutes and undergoes ubiquitina‑
tion and degradation. Once NF‑κB is released from the inhibitory 
unit IκB, the NF‑κB is then translocated into the nucleus. Upon its 
nuclear translocation, NF‑κB undergoes phosphorylation on serine 
276 in its p65 subunit and associates with surrounding chroma‑
tin components. It subsequently binds with DNA and promotes 
the transcription of proinflammatory cytokines.[48] Studies have 
also demonstrated that NF‑κB was involved in the induction of 
monocyte chemotactic protein‑1 in mesangial cell cultured under 
high glucose condition and subsequently mediated macrophage 
accumulation.[49] Moreover, the AGE–RAGE interaction activates 
TGF‑β1 signaling pathways and subsequently induces mesangial 
cell hypertrophy and glomerular sclerosis by ECM synthesis.[4] 
Therefore, AGEs’ accumulation in the kidney has been regarded 
as an index of progressive renal damage in DN.
Actually, not only the overexpression of AGEs and RAGE 
but also the higher levels of NF‑kB and TGF‑β1 in the kidney of 
STZ‑diabetic rats were alleviated by a 10‑week treatment with 
2.5 g/kg/day WLS.[36] The higher renal levels of AGEs in STZ‑di‑
Tzeng, et al. / Journal of Traditional and Complementary Medicine 3 (2013) 152-158
156
abetic rats were effectively lowered by 12 weeks of 2.8 g/kg/day 
DSS treatment.[36] Similarly, the elevated NF‑κB and TGF‑β1 pro‑
tein expressions in the kidney of STZ‑diabetic rats were reduced by 
12 weeks of DSS treatment.[37] It seems that the selected traditional 
Chinese medicinal formulas influenced not only the AGE–RAGE 
signaling but also the NF‑κB–TGF‑β1–dependent pathway to some 
extent, thus leading to attenuate the renal damage caused by the 
protein glycation reaction.
Inhibition of oxidative stress by the selected TCM formulas 
to ameliorate DN
Individuals with diabetes and experimental animal models 
exhibit high oxidative stress due to persistent and chronic hy‑
perglycemia.[50] The increased lipid peroxidation in the kidney 
implies the level of susceptibility to diabetic oxidative stress, 
leading to diabetic complications. From this viewpoint, preven‑
tion of hyperlipidemia and/or lipid peroxidation resulting from 
oxidative stress is considered to play a crucial role in protection 
from disorders associated with diabetes.[51] When considering 
AGEs from another viewpoint, Nε‑(carboxymethyl) lysine (CML), 
pentosidine, and methylglyoxal derivatives are among some of the 
well‑characterized compounds that commonly are used as AGE 
markers.[6] Particularly, CML is not only referred to as a glycoxida‑
tion product, but is also formed during the metal‑catalyzed oxida‑
tion of polyunsaturated fatty acids in the presence of protein.[52] 
Therefore, CML could serve as a general bio‑marker of oxidative 
stress resulting from carbohydrate and lipid oxidation reactions. 
We found that treatment of STZ‑diabetic rats with 12 weeks of 
DSS (2.8 g/kg/day) not only lowered the renal CML level but also 
decreased the accumulation of lipid peroxidation products in the 
kidney.[37] Ten weeks of WLS administration also successfully 
reduced the renal levels of CML or thiobarbituric acid (TBA) reac‑
tive substance, an index of endogenous lipid peroxidation, at the 
dose of 2.5 g/kg/day.[36,53] The results indicated that the beneficial 
effect of selected TCM formulas on DN was linked to reduce the 
intensity of oxidative stress under diabetic state.
Among the antioxidative enzymes, superoxide dis‑
mutase (SOD) catalyzes dismutation of the superoxide anion into 
hydrogen peroxide, while glutathione peroxidase (GSH‑Px) both 
detoxifies hydrogen peroxides and converts lipid hydroperoxides 
to non‑toxic alcohols; thus, the antioxidant enzyme activities 
could reflect antioxidant defense status.[54] The reduced activities 
of SOD and GSH‑Px in the kidney of STZ‑diabetic rats could be 
elevated by DSS.[37] The selected TCM formulas protect the kidney 
of diabetic rats from oxidative damage by enhancing enzymatic 
antioxidative defense systems could be considerable.
The selected TCM formulas for treating DN act 
independently by blocking RAS
It has long been known that hypertension is an aggravating 
factor in increased intraglomerular pressure and may be the key 
hemodynamic determinant of diabetic renal injury as well; it is 
therefore well recognized that blood pressure control is important 
in diabetic patients.[7] Angiotensin (Ang) II is known to favor 
increased TGF‑β1 production. ACEIs reduce both the generation 
of Ang II and the synthesis of TGF‑β1.
[55] In addition, Ang II is 
well recognized to be one of the major causes of mesangial matrix 
expansion in DN.[56] ACEI and ARBs have been shown to cause 
persistent normalization of blood pressure, retard the progression 
of renal failure, and markedly reduce the associated mortality.[57] 
In a previous study, the increase in Ang II concentrations in rats 
with DN was not affected by treatment with DBT, whereas the 
treatment resulted in reduced TGF‑β1 expression in the kidney.
[23] 
This finding demonstrated that DBT does not exert its renoprotec‑
tive effects through inhibition of renin–angiotensin system (RAS). 
Furthermore, WLS and DSS were observed to have no influence 
on the blood pressure in STZ‑diabetic rats.[36,37] These data have 
implications that the selected TCM formulas exhibit a renoprotec‑
tive effect in an animal model of DN by inhibiting the expression 
of TGF‑β1, which might be linked to its beneficial effect on the 
hyperglycemic state, but did not correlate with blocking intrarenal 
RAS. However, the other TCM formulas such as RF have the 
ability to suppress hyperactivity of RAS, leading to ameliorate the 
progressive renal failure in five out of six nephrectomized rats.[58] 
The pathology and mechanisms of DN are complicated, thus 
providing various formulas with different action mechanisms for 
prevention, amelioration, or treatment of DN. The renoprotective 
effects and the optimal application dose of the TCM formulas are 
worth to be evaluated further.
PERSPECTIVES AND FUTURE DIRECTIONS
Implication for practice
The findings from the selected TCM formulas are of merit in 
revealing that WLS, DBT, and DSS have anti‑diabetic properties, 
with antihyperglycemic activity accompanied by an improve‑
ment in renal functions in STZ‑diabetic rats. These selected 
TCM formulas also have the capacity to ameliorate the defective 
antioxidative defense system, leading to modulate the oxidative 
stress, thereby resulting in downregulation of NF‑κB as well 
as TGF‑β1 and, consequently, attenuation of ECM components 
such as fibronectin or type IV collagen expression in diabetic 
renal cortex tissue. The possible mechanisms of the selected 
TCM formulas on the amelioration of DN have been shown in 
Figure 2. The TCM formulas may be useful as adjuvant therapy 
in the treatment of diabetes and are also helpful to prevent and/
or delay the onset of diabetes‑induced renal injury. Until now, 
the therapeutic effects of the selected formulas including DBT, 
WLS, and DSS are limited to animal models. Using a metabo‑
lism coefficient of 6.25 to convert the effective daily oral dose 
of DBT (3.6 g/kg), WLS (2.5 g/kg), or DSS (2.8 g/kg) for rats 
into a clinical dose and assuming an average adult body weight 
of 60 kg,[59] we estimated the daily oral dose of DBT, WLS, or 
DSS applied in TCM to treat any diabetic patient in the future to 
be approximately 36, 24, and 27 g, respectively.
Implications for research
Safety is a fundamental principle in the provision of herbal med‑
icines and herbal products for health care, and a critical component 
of quality control. But there is a widespread misconception among 
most consumers and patients that “natural” always means “safe” 
and a common belief that remedies from natural origin are harmless 
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and carry no risk. In fact, the health risks of herbal remedies or TCM 
formula include direct toxic effects, contaminations such as with 
heavy metals or unlabeled pharmaceutical agents, drug interactions, 
and the indirect risk that a herb without demonstrable efficacy may 
impair, delay, or replace conventional treatments.[60] Therefore, 
World Health Organization (WHO) published the WHO guidelines 
on safety monitoring of herbal medicines in pharmacovigilance 
systems in 2004.[60] Thus, further studies should be contemplated 
to assess the long‑term benefits and safety of the selected TCM 
formulas in the treatment/and or prevention of diabetes‑induced 
renal injury and other related complications.
Most TCM remedies are formulated to contain different herbs 
in combination in order to enhance the curative efficacy and also 
reduce the side effects; it is relatively difficult to figure out which 
component from the formula is the main effective monomer for 
the therapy of DN. Further studies will be required to identify 
the ingredients and/or chemicals in the TCM formulas, which are 
responsible for the beneficial renal effects observed.
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